These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16462825)

  • 21. Future directions in the treatment of malignant gliomas with temozolomide.
    Prados MD
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):41-6. PubMed ID: 10866349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatal outcome related to carmustine implants in glioblastoma multiforme.
    Gallego JM; Barcia JA; Barcia-Mariño C
    Acta Neurochir (Wien); 2007 Mar; 149(3):261-5; discussion 265. PubMed ID: 17334672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [I. Photodynamic therapy for glioblastoma].
    Akimoto J
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):678-82. PubMed ID: 26242004
    [No Abstract]   [Full Text] [Related]  

  • 24. Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
    De Vita S; De Matteis S; Laurenti L; Chiusolo P; Reddiconto G; Fiorini A; Leone G; Sica S
    Ann Hematol; 2005 Oct; 84(11):760-2. PubMed ID: 16044311
    [No Abstract]   [Full Text] [Related]  

  • 25. Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
    Goldman B
    J Natl Cancer Inst; 2007 Apr; 99(7):504-5. PubMed ID: 17405993
    [No Abstract]   [Full Text] [Related]  

  • 26. Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences.
    Fazeny-Dörner B; Mader RM; Piribauer M; Rizovski B; Stögermaier B; Marosi C
    Anticancer Drugs; 2004 Jun; 15(5):495-8. PubMed ID: 15166624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
    Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
    Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The fallacy of single-agent chemotherapy for cancer.
    Friedman HS; Maxwell J
    J Clin Oncol; 2007 Aug; 25(23):3550; author reply 3550-1. PubMed ID: 17687162
    [No Abstract]   [Full Text] [Related]  

  • 30. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
    Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
    No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic radiotherapy for glioblastoma in the elderly.
    Tartarone A; Ardito R; Romano C
    N Engl J Med; 2007 Jul; 357(2):196; author reply 196. PubMed ID: 17626310
    [No Abstract]   [Full Text] [Related]  

  • 34. Highlights in Central Nervous System Tumors.
    Hertenstein A; Platten M; Wick W
    JAMA Oncol; 2016 Dec; 2(12):1535-1536. PubMed ID: 27658179
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.
    Franceschi E; Minichillo S; Brandes AA
    CNS Drugs; 2017 Aug; 31(8):675-684. PubMed ID: 28681349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting glioblastoma: from dream to reality.
    Mikhael E; Kourie HR
    Biomark Med; 2021 Apr; 15(6):385-388. PubMed ID: 33709784
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunotherapy and radiation in glioblastoma.
    Sahebjam S; Sharabi A; Lim M; Kesarwani P; Chinnaiyan P
    J Neurooncol; 2017 Sep; 134(3):531-539. PubMed ID: 28567588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current management of glioblastoma multiforme.
    Grossman SA; Batara JF
    Semin Oncol; 2004 Oct; 31(5):635-44. PubMed ID: 15497116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol.
    Fischer Jde S; Carvalho PC; Neves-Ferreira AG; da Fonseca CO; Perales J; Carvalho Mda G; Domont GB
    J Exp Ther Oncol; 2008; 7(4):285-90. PubMed ID: 19227008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic supportive care of children with central nervous system tumors.
    Cullen PM
    J Pediatr Oncol Nurs; 1995 Oct; 12(4):230-2. PubMed ID: 7495528
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.